Innospec (IOSP) Receives News Impact Rating of 0.11
Press coverage about Innospec (NASDAQ:IOSP) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Innospec earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media coverage about the specialty chemicals company an impact score of 47.1969495408253 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Innospec, Inc. (IOSP) CEO Patrick Williams on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Innospec (IOSP) Announces Earnings Results, Misses Expectations By $0.05 EPS (americanbankingnews.com)
- Innospec: 2Q Earnings Snapshot (finance.yahoo.com)
- Innospec Reports Second Quarter 2018 Financial Results (finance.yahoo.com)
- Innospec (IOSP) Q2 Earnings Miss Estimates, Sales Up Y/Y (zacks.com)
IOSP has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Innospec from a “sell” rating to a “hold” rating in a research note on Thursday, April 19th. BidaskClub raised shares of Innospec from a “hold” rating to a “buy” rating in a research note on Thursday, April 19th. ValuEngine downgraded shares of Innospec from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 2nd. KeyCorp upped their price target on Innospec from $80.00 to $86.00 and gave the stock an “overweight” rating in a research report on Friday, July 13th. Finally, Johnson Rice raised Innospec from an “accumulate” rating to a “buy” rating in a research report on Tuesday, April 24th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $78.67.
Innospec (NASDAQ:IOSP) last issued its quarterly earnings results on Tuesday, August 7th. The specialty chemicals company reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.05). The business had revenue of $358.10 million for the quarter. Innospec had a return on equity of 13.83% and a net margin of 4.45%. equities analysts forecast that Innospec will post 4.5 earnings per share for the current year.
In related news, insider Philip Curran sold 2,000 shares of the company’s stock in a transaction on Monday, May 14th. The stock was sold at an average price of $73.63, for a total value of $147,260.00. Following the transaction, the insider now directly owns 4,218 shares of the company’s stock, valued at approximately $310,571.34. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Milton C. Blackmore sold 444 shares of the company’s stock in a transaction on Friday, June 1st. The shares were sold at an average price of $76.83, for a total value of $34,112.52. Following the completion of the transaction, the director now directly owns 6,444 shares in the company, valued at $495,092.52. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 15,841 shares of company stock worth $1,209,657. Insiders own 2.02% of the company’s stock.
Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals for use as fuel additives, ingredients for personal care, home care, agrochemical, mining and other applications, and oilfield chemicals worldwide. It operates through four segments: Fuel Specialties, Performance Chemicals, Oilfield Services, and Octane Additives.
Further Reading: Trading Strategy Methods and Types
Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.